☆ 4.5 Article

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients

LUNG CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors

Richard Riedel et al.

Summary: This study describes the resistance mechanisms to MET inhibition in MET-dependent non-small cell lung cancer patients, including MET exon 14 skipping mutation, MET amplification, and MET fusion. Analysis of patient samples revealed on-and off-target resistance mechanisms, such as KRAS mutations and HER2 amplification. Switching between different types of kinase inhibitors can lead to repeated responses in some patients.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements

Yongchang Zhang et al.

Summary: This retrospective study investigated the association between disease progression pattern and acquired resistance mechanism in patients with ROS1-rearranged non-small-cell lung cancer treated with crizotinib. The study found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly in patients with extracranial-only disease progression. The findings emphasize the importance of rebiopsy and gene testing for subsequent-line therapeutic management.

NPJ PRECISION ONCOLOGY (2022)

添加到收藏夹

Review Oncology

ROS1-dependent cancers - biology, diagnostics and therapeutics

Alexander Drilon et al.

Summary: The proto-oncogene ROS1 encodes a receptor tyrosine kinase without a well-defined physiological role, and somatic chromosomal fusions involving ROS1 lead to chimeric oncoproteins that drive various cancers. Although ROS1-directed tyrosine kinase inhibitors show therapeutic efficacy, resistance mechanisms remain unclear.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Rafal Dziadziuszko et al.

Summary: Entrectinib continues to show a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including those with central nervous system metastases.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Nasser H. Hanna et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F. Mosele et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

Arnaud Jeanson et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Matthias Scheffler et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Sebastian Michels et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Neal I. Lindeman et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Letter Medicine, General & Internal

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer

Konstantinos Arnaoutakis

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Monika A. Davare et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

添加到收藏夹

Article Oncology

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability

Matthias Scheffler et al.

ONCOTARGET (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Jianjiong Gao et al.

SCIENCE SIGNALING (2013)

添加到收藏夹

Article Oncology

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Kristin Bergethon et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Genetics & Heredity

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer et al.

NATURE GENETICS (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Predicting the Functional Effect of Amino Acid Substitutions and Indels

Yongwook Choi et al.

PLOS ONE (2012)

添加到收藏夹

Editorial Material Oncology

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Ethan Cerami et al.

CANCER DISCOVERY (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.